UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934 FOR THE PERIOD ENDED September 30, 2002
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD From _____________ to __________________
..
Commission File Number 333-60362
NEURO BIOSCIENCE, INC.
----------------------
(Exact name of registrant as specified in its charter)
Filed Effective November 14, 2002
Utah 87-0670014
---- ----------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
1251 Avenue of the Americas
New York, NY 10020
---------------------------
(Address of principal executive officers)
(212) 591-0256
---------------
(Registrant's telephone number, including area code)
Mortgage Professionals Lead Source, Inc., 959 East Akers Way, Sandy, UT 84094
-------------------------------------------------------------------------------
(Former name, former address and former fiscal year, if changed since last
report)
Indicate by check mark whether the registrant (l) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter periods that the registrant was
required to file such reports), X Yes No; and (2) has been subject to
such filing requirements for the past 90 days: X Yes No
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS
Indicate by check mark whether the registrant has filed all documents and
reports required to be filed by Sections 12, 13, or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan
confirmed by the court. Yes No Not Applicable
APPLICABLE ONLY TO CORPORATE ISSUERS
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practical date.
Common Stock: 619,300 shares issued as of November 10, 2002. No Par Value.
Authorized - 50,000,000 common voting shares. The company has only one class of
shares.
1
INDEX
Neuro Bioscience, Inc.
KNOWN AS MORTGAGE PROFESSIONALS LEAD SOURCE, INC.
FOR THE QUARTER ENDING SEPTEMBER 30, 2002
NO ACCOUNTING CONTAINED HEREIN REELECTS THE ACQUISITION OF NEURO BIOSCIENCE,
INC. WHICH BECAME EFFECTIVE NOVEMBER 14, 2002 AND WHICH WILL BE SUBSEQUENTLY
REPORTED.
Part I. Financial Information
Item 1. Financial Statements
Condensed Balance Sheets - September 30, 2002 (Unaudited).
Condensed Statements of Operations (Unaudited) - For the
Nine Months Ended September 30, 2002 and For the Period
February 16, 2001 (Date of Inception) Through September 30,
2001 and for the Three Months Ended September 30, 2002 and
2001 and For the Period from February 16, 2001 (Date of
Inception) through September 30, 2002.
Condensed Statements of Cash Flows (Unaudited) - For Nine
Months Ended September 30, 2002 and For the Period February
16, 2001 (Date of Inception) through September 30, 2001 and
2002.
Notes to Condensed Financial Statements (Unaudited)
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations
Item 3. Controls and Procedures
Part II. Other Information
Item 1. Legal Proceedings
Item 2. Changes in Securities and Use of Proceeds
Item 4. Submission of Matters to a Vote of Security Holders
Item 6. Exhibits and Reports on Form 8-K
Signatures
Part I - Financial Information
Item 1. Financial Statements
MORTGAGE PROFESSIONALS LEAD SOURCE, INC.
(A Development Stage Enterprise)
CONDENSED BALANCE SHEETS
(UNAUDITED)
September 30, December 31,
2002 2001
---------- ----------
ASSETS
Current Assets
Cash $ 28,450 $ 99,910
---------- ----------
Total Assets $ 28,450 $ 99,910
========== ==========
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current Liabilities
Accounts payable $ 6,991 $ 23,104
---------- ----------
Total Current Liabilities 6,991 23,104
---------- ----------
Stockholders' Equity (Deficit)
Common stock , no par value; 50,000,000
shares authorized; 619,300 shares
issued and outstanding 126,592 126,592
Deficit accumulated during the
development stage (105,133) (49,786)
---------- ----------
Total Stockholders' Equity (Deficit) 21,459 76,806
---------- ----------
Total Liabilities and Stockholders'
Equity (Deficit) $ 28,450 $ 99,910
========== ==========
The accompanying notes are an integral part of these
condensed financial statements.
2
MORTGAGE PROFESSIONALS LEAD SOURCE, INC.
(A Development Stage Enterprise)
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
For the Period For the Period
February 16, February 16,
For the 2001 (Date of 2001 (Date of
Nine Months Inception) For the Three Months Inception)
Ended Through Ended September 30, Through
September 30, September 30, ------------------------- September 30,
2002 2001 2002 2001 2002
----------- ----------- ----------- ----------- -----------
Revenue $ 300 $ - $ - $ - $ 300
General and administrative
expenses 55,647 26,553 25,690 1,130 105,433
----------- ----------- ----------- ----------- -----------
Net Loss $ (55,347) $ (26,553) $ (25,690) $ (1,130) $ (105,133)
=========== =========== =========== =========== ===========
Basic and Diluted Loss
Per Share $ (0.09) $ (0.05) $ (0.04) $ (0.00)
=========== =========== =========== ===========
Weighted Average Number
of Shares Outstanding 619,000 510,000 619,000 510,000
=========== =========== =========== ===========
The accompanying notes are an integral part of these
condensed financial statements.
3
MORTGAGE PROFESSIONALS LEAD SOURCE, INC.
(A Company in the Development Stage)
CONDENSED STAEMENTS OF CASH FLOWS
(UNAUDITED)
For the Period
From February 16, 2001
For the (Date of Inception)
Nine Through
Months Ended --------------------
September September September
30, 2002 30, 2001 30, 2002
--------- --------- ----------
Cash Flows From Operating Activities
Net loss $ (55,347) $ (26,553) $ (105,133)
Stock issued for services - 25,000 25,000
Changes in current assets and liabilities:
Prepaid expense - (4,775) -
Accounts payable (16,113) 400 6,991
--------- --------- ----------
Net Cash Used in Operating
Activities (71,460) (5,928) (73,142)
--------- --------- ----------
Net Cash Used in Investing
Activities - - -
--------- --------- ----------
Cash Flows From Financing Activities
Proceeds from issuance of common stock - 5,000 114,300
Offering costs on initial public - (1m300) (27,708)
Cash received on receivable
from shareholders - 15,000 15,000
--------- --------- ----------
Net Cash Provided by Financing
Activities - 18,700 101,592
--------- --------- ----------
Net Increase (Decrease) in Cash (71,460) 12,772 28,450
Cash at Beginning of Period 99,910 - -
--------- --------- ----------
Cash at End of Period $ 28,450 $ 12,772 $ 28,450
========= ========= ==========
Non-Cash Investing and Financing Activities:
Common stock issued for receivable
from shareholders $ - $ 15,000 $ 15,000
Accrual of deferred offering costs $ - $ 26,408 $ 26,408
The accompanying notes are an integral part of these
condensed financial statements.
4
MORTGAGE PROFESSIONALS LEAD SOURCE, INC.
(A Company in the Development Stage)
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Interim Financial Statements-The accompanying financial statements are
unaudited. In the opinion of management, all necessary adjustments (which
include only normal recurring adjustments) have been made to present fairly the
financial position, results of operations and cash flows for the periods
presented. Certain information and disclosures normally included in financial
statements prepared in accordance with accounting principles generally accepted
in the United States of America have been condensed or omitted. It is suggested
that these condensed financial statements be read in conjunction with the
Company's financial statements and notes thereto included in the Form 10-KSB
dated March 25, 2002. The results of operations for the nine months ended
September 30, 2002 are not necessarily indicative of the operating results to be
expected for the full year ending December 31, 2002.
Business Condition - The accompanying financial statements have been prepared on
a going concern basis, which contemplates the realization of assets and the
satisfaction of liabilities in the normal course of business. During the period
from February 16, 2001 (date of inception) through June 30, 2002, the Company
incurred a net loss and accumulated deficit of $105,133 and used cash from
operations of $73,142. These factors, among others, indicate that the Company
may be unable to continue as a going concern. The accompanying financial
statements do not include any adjustments relating to the carrying amount and
classification of recorded assets or the amount and classification of
liabilities that might be necessary should the Company be unable to continue as
a going concern. As of December 31, 2001, the Company had received gross
proceeds of $109,300 from its initial registered public offering. The Company
incurred costs totaling $27,708 in conjunction with this offering. Subsequent
to September 30, 2002 (see Note 3), the Company entered into a merger agreement
with another company. There are no assurances that the reorganized company will
be profitable.
NOTE 2 - CONSULTING AGREEMENT
In July 2002, the Company entered into an agreement with Belsen Getty for
consulting services related to merger and acquisition possibilities, future
capital funding, and related financial matters. The Company paid Belsen Getty
$25,000 and principle shareholders agreed to transfer 329,000 of their existing
capital stock to Belsen Getty.
NOTE 3 - LETTER OF INTENT AND SUBSEQUENT STOCK EXCHANGE AGREEMENT
On September 26, 2002, the Company entered into a Letter of Intent with Neuro
Bioscience, Inc. ("Neuro"), by which the Company would fully acquire Neuro's
stock in exchange for the issuance of 9,000,000 restricted shares of common
stock of the Company. On November 12, 2002, the Company consummated a Share
Exchange through a special shareholder meeting in which the ownership of the
Company changed by a majority share acquisition of Neuro. After the Share
Exchange, Neuro owns approximately 93.4% of the total issued and outstanding
shares of the Company. Also in connection with the transaction, management of
the Company changed through the nomination and election of a new board proposed
by Neuro.
5
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
Forward-Looking Information
Certain statements in this Section and elsewhere in this report are forward-
looking in nature and relate to trends and events that may affect the Company's
future financial position and operating results. Such statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The terms "expect,""anticipate,""intend," and "project" and
similar words or expressions are intended to identify forward-looking
statements. These statements speak only as of the date of this report. The
statements are based on current expectations, are inherently uncertain, are
subject to risks, and should be viewed with caution. Actual results and
experience may differ materially from the forward-looking statements as a result
of many factors, including changes in economic conditions in the markets served
by the company, increasing competition, fluctuations in raw materials and energy
prices, and other unanticipated events and conditions. It is not possible to
foresee or identify all such factors. The company makes no commitment to update
any forward-looking statement or to disclose any facts, events, or circumstances
after the date hereof that may affect the accuracy of any forward-looking
statement.
Results of Operations
Mortgage Professionals Lead Source, Inc. ("MPLS") was incorporated in Utah on
February16, 2001 and has been involved primarily to this point in start-up
operations including incorporation, initial organization and an initial public
offering ("IPO") of its shares and start-up marketing operations. The offering
became effective with the Securities and Exchange Commission (SEC) on August 16,
2001 and in the State of Utah on such date by coordination. The offering was
closed on December 5, 2001 after raising $109,300 in gross proceeds.
As previously reported on Form 8-K, the Company consummated a Share Exchange
through a Special Shareholder Meeting on November 12, 2002 in which the
ownership of the Company changed by a majority share acquisition of a privately
held Company known as Neuro Bioscience, Inc., a Delaware Corporation having its
principal place of business in New York City, NY in exchange to NBI's
shareholders of most of the Company's stock.
As reported, this exchange resulted in Neuro Bioscience, Inc. being fully
acquired by Mortgage Professionals Lead Source, Inc. which then changed its name
of record by the filing of Articles of Share Exchange in the State of Utah to
Neuro Bioscience, Inc. as of November 14, 2002. As a result of such Share
Exchange the following significant events have occurred in the Company:
(1) The Company has changed its business purpose from attempting to
provide mortgage refinancing services to the research, development and potential
marketing of experimental new pharmaceutical products through its fully owned
and sole operating subsidiary, Neuro Bioscience, Inc.
5
(2) Management of the Company has changed through the nomination and
election of a new Board proposed by Neuro Bioscience, Inc. as more fully set-out
in the 8-K filings by the Company.
(3) The Company has changed its business location from Utah to 1251 Avenue
of the Americas, New York, NY 10020.
(4) Essentially all of the remaining liquid assets of the Company were
employed and expended to pay for costs and services related to the Share
Exchange Agreement.
(5) No value determination of the intangible assets, primarily five
development stage pharmaceutical products owned by Neuro Bioscience, Inc., has
been made at this time. The Company would intend to file a subsequent 8-K
report employing consolidated financial statements for the combined entities
within a sixty day period from the filing of its last 8-K on November 14, 2002.
(6) The principal ownership of the Company now is comprised of five
British based business entities who have previously been associated with Neuro
Bioscience, Inc. and who collectively own approximately 93.4% of the issued and
outstanding stock of the Company pursuant to the Share Exchange. These
matters were more fully detailed in the concurrently filed 8-K Report and
documents.
(7) It is not certain what impact, if any, the reorganization will have
upon the limited trading market of the Company, but the Company will most likely
obtain a new trading symbol, CUSIP number and federal tax number.
AS A RESULT OF THE FOREGOING TRANSACTIONS, EACH PERSON REVIEWING THIS REPORT
SHOULD FULLY UNDERSTAND THAT THE ACCOUNTING AND INFORMATION SUPPLIED AS PART OF
THIS REPORT IS FOR THE PERIOD PRIOR TO THIS REORGANIZATION THROUGH SEPTEMBER 30,
2002 AND WILL LIKELY BE SUBSTANTIALLY CHANGED AND UPDATED DUE TO THE
REORGANIZATION TO BE REPORTED PURSUANT TO THE FUTURE ANTICIPATED FILING OF
CONSOLIDATED FINANCIALS AS DESCRIBED ABOVE.
The accumulated deficit for MPLS during the development stage resulting from
general and administrative and expenses was $105,133 as of September 30, 2002.
There remained approximately $28,450 of net proceeds from the offering as of
September 30, 2002. However, as noted above, substantially all of these
proceeds have been subsequently expended related to the Share Exchange.
The Company has abandoned implementation of its initial marketing plan to
attempt to secure refinancing commitments from home owners and small businesses
on existing mortgage loans through mass marketing techniques.
6
The overhead for the Company was approximately $4,600 per month including
estimated expenses for reporting and operating as a public trading company. It
is intended that overhead will substantially change as the Company moves to
implement future operations from its new base of operations in New York, New
York. No assurance is made or implied the Company can continue to exist, or
that it will be successful in its new business opportunities. To date, neither
MPLS or Neuro Bioscience has realized any revenues or income.
Liquidity and Sources of Capital
The Company will seek subsequent private placement financing funds, loans or
other means to continue its operations, though there can be no assurance or
warranty that any such funds will be available. The target range of this
funding is $5 to $10 million over the next six to twelve months.
Plan of Operations
The company is presently modifying its business plan to attempt to integrate
active development, testing and potential marketing of its five development
stage pharmaceutical products. Neuro is engaged in the early development stage
of five pharmaceutical products which are intended to treat various human
central nervous system disorders and symptoms related to diseases such as
Parkinsons Disease, Alzheimers and other central nervous system disorders. It
should be noted that these drugs are in the early development stages and that no
approval by the FDA or other drug regulatory authority has been obtained for the
marketing or distribution of these drugs and no assurance or warranty that such
drugs will ultimately be approved, marketed or be efficacious can be made or
given by the Company.
Item 3. Controls and Procedures
(a) The Company maintains controls and procedures designed to ensure that
information required to be disclosed in the reports that the Company
files or submits under the Securities Exchange Act of 1934 is
recorded, processed, summarized and reported within the time periods
specified in the rules and forms of the Securities and Exchange
Commission. Based upon their evaluation of those controls and
procedures performed with 90 days of the filing date of this report,
the chief executive officer and the principal financial officer of the
Company concluded that the Company's disclosure controls and
procedures were adequate.
(b) Changes in internal controls. The Company made no significant
changes in its internal controls or in other factors that could
significantly affect these controls subsequent to the date of
the evaluation of those controls by the chief executive officer
and principal financial officer.
7
Part II - Other Information
Item 1. Legal Proceedings
The Company is not presently engaged in any legal proceedings, nor does it know
of any claims for or against the company by any party.
Item 2. Changes in Securities and Use of Proceeds
The company has not had any change in its securities since its last report
filing on Form SB-1.
In accordance with SEC Rule 463 the company reports the use of proceeds to date
from its initial public offering "IPO" completed on December 5, 2001:
1. Gross proceeds sold - $109,300.
2. Accrued offering related costs including printing, accounting, legal
and related filing fees - $27,708.
3. Amount expended to September 30, 2002 on marketing and operations -
$53,142.
4. Approximate amounts expended related to Share Exchange - $6,600.
5. Approximate amount expended subsequent to September 30, 2002 unrelated
to stock exchange.
6. Approximate balance remaining - $10,500*
*To be substantially expended pursuant to accrued but currently unpaid
costs primarily related to SEC filings and share exchange.
Item 4. Submission of Matters to a Vote of Security Holders
During the present quarter there has been no matter submitted to security
holders for a vote. Subsequent to the date of this Report, the Company held a
Special Shareholders Meeting on November 12, 2002 to approve the terms of the
Share Exchange including the change of name as generally described above. These
changes were approved by majority vote, and the new Board was also elected by
majority vote as reported on the Form 8-K.
Item 6. Exhibits and Reports on Form 8-K:
The Company has filed two reports on Form 8-K subsequent to September 30, 2002
but prior to filing this report:
8
(i) An 8-K was filed October 2, 2002 describing the Letter
of Intent and proposed terms of Share Exchange with Neuro
Bioscience, Inc.
(ii) A subsequent 8-K was filed November 14, 2002 describing
the definitive terms of the Share Exchange, name change and
shareholder vote.
EXHIBITS:
99.1 Certification under Section 90-6 of the Sarbanes-Oxley
Act (18 U.S.C. SECTION 1350)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant
has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
REGISTRANT: MORTGAGE PROFESSIONAL LEAD SOURCE, INC.
Date: November 14, 2002 By: /s/ Gregory Willits
_________________________________
Mr. Gregory Willits
President - (Resigning)
Date: November 14, 2002 By: /s/ Michael J. Christensen
_________________________________
Mr. Michael J. Christensen
Chief Financial and Accounting Officer
(Resigning)
9
EXHIBIT 99.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Mortgage Professional Lead Source,
Inc. now known as Neuro Bioscience, Inc. (the "Company") on Form 10-QSB for the
period ending September 30, 2002, as filed with the Securities and Exchange
Commission on the date hereof (the "Report"), we, Mr. Gregory Willits, President
and Mr. Michael J. Christensen, Chief Financial and Accounting Officer of the
Company, certify to the best of our knowledge, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that:
(1) The report fully complies with the requirements of section 13 (a) or
15 (d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.
/s/ Gregory Willits
___________________________________
Mr. Gregory Willits
President
Michael J. Christensen
___________________________________
Mr. Michael J. Christensen
Chief Financial Officer
10
Attachment A
CERTIFICATION
I, Gregory Willits, President, of Mortgage Professionals Lead Source, Inc
certify that:
(1) I have reviewed this quarterly report on Form 10-QSB of Mortgage
Professionals Lead Source, Inc.;
(2) Based on my knowledge, this quarterly report does not contain any
untrue statement of a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this quarterly report;
(3) Based on my knowledge, the financial statements, and other financial
information included in this quarterly report fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;
(4) The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
(a) designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this
quarterly report is being prepared;
(b) evaluated the effectiveness of the registrant's disclosure
controls and procedures as of a date within 90 days prior to the
filing date of this quarterly report (the "Evaluation Date'); and
(c) presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on
our evaluation as of the Evaluation Date;
(5) The registrant's other certifying officers and I have disclosed, based
on our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's board of directors (or persons performing the
equivalent function):
(a) all significant deficiencies in the design or operation of
internal controls which could adversely affect the registrant's
ability to record, process, summarize and report financial data
and have identified for the registrant's auditors any material
weaknesses in internal controls; and
11
(b) any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrant's
internal controls; and
(6) The registrant's other certifying officers and I have indicated in
this quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.
DATE: November 14, 2002
/s/ Gregory Willits
__________________________________
Gregory Willits
President
Attachment A
12
CERTIFICATION
I, Michael J. Christensen, Chief Financial Officer, of Mortgage Professionals
Lead Source, Inc certify that:
(1) I have reviewed this quarterly report on Form 10-QSB of Mortgage
Professionals Lead Source, Inc.;
(2) Based on my knowledge, this quarterly report does not contain any
untrue statement of a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this quarterly report;
(3) Based on my knowledge, the financial statements, and other financial
information included in this quarterly report fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;
(4) The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
(a) designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this
quarterly report is being prepared;
(b) evaluated the effectiveness of the registrant's disclosure
controls and procedures as of a date within 90 days prior to the
filing date of this quarterly report (the "Evaluation Date'); and
(c) presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on
our evaluation as of the Evaluation Date;
(5) The registrant's other certifying officers and I have disclosed, based
on our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's board of directors (or persons performing the
equivalent function):
13
(a) all significant deficiencies in the design or operation of
internal controls which could adversely affect the registrant's
ability to record, process, summarize and report financial data
and have identified for the registrant's auditors any material
weaknesses in internal controls; and
(b) any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrant's
internal controls; and
(6) The registrant's other certifying officers and I have indicated in
this quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.
DATE: November 14, 2002
Michael J. Christensen
_______________________
Michael J. Christensen
Chief Financial Officer
14